Trial Profile
A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Gusacitinib (Primary)
- Indications Chronic lymphocytic leukaemia; Myelofibrosis; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Asana BioSciences; Kirilys Therapeutics
- 23 Jan 2017 Status changed from recruiting to completed.
- 27 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 27 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.